Fig. 4Figure 4
Inhibition of NF-κB pathway in vivo restores brain endothelial Wnt/β-catenin signaling and attenuates LPS-induced BBB leakage and neuroinflammation. A , Schematic illustration of experimental design. The NF-κB pathway inhibitor BAY 11-7085 (5 mg/kg) or vehicle control (DMSO) was intraperitoneally (i.p.) injected to mice at 30 min after LPS or saline injection. B , Mortality rate of mice at 24 h following vehicle ( n = 10 mice), LPS + vehicle ( n = 14 mice), or LPS + BAY 11-7085 ( n = 15 mice) treatment. C , Body weight change of the mice at 24 h after vehicle ( n = 10 mice), LPS + vehicle ( n = 9 mice), or LPS + BAY 11-7085 ( n = 10 mice) treatment. D , Co-immunofluorescence staining of NF-κB p65 and CD31 in the brain cortex and its quantifications. NF-κB p65 signal in endothelial cells was selectively quantified. E , Co-immunofluorescence staining of VCAM1 and CD31 in the brain cortex and its quantifications. F , Co-immunofluorescence staining of LEF1 and CD31 in the brain